On June 5, 2020 As the Annual Oncology Meeting transitions to a virtual program, Physicians’ Education Resource reported that (PER) launched "Oncology NOW," a series of free accredited live and interactive webcasts that delivers expert insights, deeper analysis, and critical updates on a variety of therapeutic areas in oncology and hematology (Press release, Physicians’ Education Resource, JUN 5, 2020, View Source [SID1234560872]). PER is committed to producing immersive digital programming that keeps oncologists connected with the latest developments from the annual oncology meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As the leading go-to resource for continuing medical education (CME), it is our responsibility to provide health care providers with in-depth education adjunct to the Annual Oncology Meeting," said Phil Talamo, president of PER. "Through our innovative online programming, we are hosting 11 cutting-edge virtual satellite symposia through our ‘Oncology NOW’ webcast series, working with world renowned faculty to help translate emerging science and new data to better patient care"
The PER "Oncology Now" webcasts are listed below. Details will be released in the coming weeks about the remaining programs.
"Exploring Future Applications of HER2/3-Targeted Therapies Across Multiple Tumor Types"
"Expert Perspectives in Relapsed/Refractory DLBCL: A Look to the Future of Care"
"Hepatocellular Carcinoma Tumor Board: The Experts Address Novel Regimens and Emerging Sequencing Considerations"
"Integrating the Evidence to Optimize Treatment for Patients With Advanced RCC: An Expert Tumor Board Discussion"
"Medical Crossfire: Novel Applications of Liquid Biopsies Across Cancer Care"
"Medical Crossfire: How Can We Maximize Immuno-Oncology Strategies in Small Cell Lung Cancers?"
"Medical Crossfire: Emerging Applications to Optimize and Individualize AML Treatment"
"The Latest Advances on NEDD8 Inhibition for Treatment of Higher-Risk MDS and Other Hematologic Malignancies"
Accredited by the Accreditation Council for Continuing Medical Education, each webcast is approved for 2.0 AMA PRA Category 1 Credits for physicians.
The "Oncology NOW" webcast series is supported by educational grants from AbbVie, Agios Pharmaceuticals Inc., AstraZeneca, Daiichi Sankyo Inc., Eisai Inc., Exelixis Inc., Foundation Medicine Inc., Genentech Inc., Grail, Guardant Health Inc., Lilly, Merck & Co. Inc., MorphoSys US Inc. and Takeda Oncology.